An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations.

All treated Population consisted of all participants who received at least one dose of GSK3145095. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

All adverse events were analyzed using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Graded from Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE. Higher grade indicates more severe condition. Number of participants with maximum severity grades were presented.

All treated Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

All adverse events were to be analyzed using NCI-CTCAE Version 5.0. Graded from Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE. Higher grade indicates more severe condition.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

All toxicities were graded using NCI-CTCAE version 5.0. An AE was considered a DLT if it occurred during the first 28 days of treatment, was considered by the investigator to be clinically relevant, and met one of the following DLT criteria: hematologic toxicity: Grade 4 neutropenia, febrile neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, Grade 3 thrombocytopenia with bleeding; Grade 3 or greater non-hematologic toxicity, any Grade 2 ocular toxicity requiring systemic steroids.

All treated Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

All toxicities were graded using NCI-CTCAE version 5.0. An AE was considered a DLT if it occurred during the first 28 days of treatment, was considered by the investigator to be clinically relevant, and met one of the following DLT criteria: hematologic toxicity: Grade 4 neutropenia, febrile neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, Grade 3 thrombocytopenia with bleeding; Grade 3 or greater non-hematologic toxicity, any Grade 2 ocular toxicity requiring systemic steroids.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

A participant's disease status and determination of disease progression at post Baseline visits was to be evaluated by the local investigator's assessments by RECIST version 1.1. The overall response rate (ORR)-CR and PR was to be determined by the investigator assessment of the participants computed tomography (CT) or magnetic resonance imaging (MRI) using RECIST version 1.1 criteria for target lesions. ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria. PR is when there is at least 30 percent decrease in sum of the longest diameter of the target lesions. Complete Response is when there is disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 millimeters (mm).

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

A participant's disease status and determination of disease progression at post Baseline visits was to be evaluated by the local investigator's assessments by RECIST version 1.1. The overall response rate (complete response and partial response) was to be determined by the investigator assessment of the participants CT or MRI using RECIST version 1.1 criteria for target lesions. ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria. Partial Response is when there is at least 30 percent decrease in sum of the longest diameter of the target lesions. Complete Response is when there is disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 mm.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 4 was not initiated.

Best overall response is defined as the best unconfirmed response (Complete Response [CR] > Partial Response [PR] > Stable Disease [SD] [or non-CR/non-PD] > Progressive Disease [PD] > Not Evaluable [NE]) from treatment start date until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST version 1.1 Criteria. The BOR rate is defined as the percentage of participants with each best unconfirmed response category. Participants with unknown or missing responses were treated as non-responders, i.e., these participants were included in the denominator when calculating percentages of response.

All treated Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Best overall response is defined as the best unconfirmed response (CR > PR > SD [or non-CR/non-PD] > PD] > NE) from treatment start date until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST 1.1 Criteria. The BOR rate is defined as the percentage of participants with each best unconfirmed response category. Participants with unknown or missing responses were treated as non-responders, i.e., these participants were included in the denominator when calculating percentages of response.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

PFS is defined as time from the date of first dose to the date of disease progression according to clinical or radiological assessment or death due to any causes, whichever occurs earliest. If the participant received subsequent anti-cancer therapy prior to the date of documented events, PFS was to be censored at the last adequate assessment (e.g., assessment where visit level response is confirmed response, partial response or stable disease) prior to the initiation of therapy. Otherwise, if the participant did not have a documented date of event, PFS was to be censored at the date of the last adequate assessment.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

PFS is defined as time from the date of first dose to the date of disease progression according to clinical or radiological assessment or death due to any causes, whichever occurs earliest. If the participant received subsequent anti-cancer therapy prior to the date of documented events, PFS was to be censored at the last adequate assessment (e.g., assessment where visit level response is confirmed response, partial response or stable disease) prior to the initiation of therapy. Otherwise, if the participant did not have a documented date of event, PFS was to be censored at the date of the last adequate assessment.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 4 was not initiated.

Overall survival is defined as time from the date of first dose to the date of death due to any cause. If a participant does not have a documented date of death, time of death is censored at the date of last contact.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Overall survival is defined as time from the date of first dose to the date of death due to any cause. If a participant does not have a documented date of death, time of death is censored at the date of last contact.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 4 was not initiated.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or other situations.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 4 was not initiated.

All adverse events were planned to be analyzed using NCI-CTCAE Version 5.0. Graded from Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE. Higher grade indicates more severe condition.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

All adverse events were planned to be analyzed using NCI-CTCAE Version 5.0. Graded from Grade 1: mild asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL, Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4: Life-threatening consequences; urgent intervention indicated, Grade 5: death related AE. Higher grade indicates more severe condition.

All treated Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 4 was not initiated.

Blood samples were collected at the indicated time points for the determination of AUC(0-t) following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

Pharmacokinetic (PK) Population. The PK Population consisted of all participants from the All-Treated Population for whom a PK sample was obtained and analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following single dose of GSK3145095 on Day 1 and was to be calculated by standard non-compartmental analysis.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of AUC (0-tau) following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-tau) following single dose of GSK3145095.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Cmax following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Cmin following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmin following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of tmax following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of CL/F following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of CL/F following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Vz/F following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of V/F following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of t1/2 following single dose of GSK3145095 on Day 1 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of AUC (0-t) following repeat dose of GSK3145095 on Day 15 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of AUC (0-tau) following repeat dose of GSK3145095 on Day 15 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-tau) following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Cmax following repeat dose of GSK3145095 on Day 15 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Cmin following repeat dose of GSK3145095 on day 15 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmin following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of tmax following repeat dose of GSK3145095 and was calculated by standard non-compartmental analysis.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of CL/F following repeat dose of GSK3145095 on Day 15. For accurate estimation of CL/F following repeated administration, it is imperative that steady state has been achieved. As the attainment of steady state could not be confirmed with certainty, CL/F was not computed following repeated dose.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of CL/F following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of Vz/F following repeat dose of GSK3145095 on Day 15. As t1/2 following repeated administration could not be computed, Vz/F whose estimation is dependent upon the t1/2 could not be estimated as well.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of V/F following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at the indicated time points for the determination of t1/2 following repeat dose of GSK3145095 on Day 15. t1/2 following repeated administration was not computed because duration of observation (12 hours from the morning dose) was too short (less than 2 times the average half-life observed after the first dose) for its accurate estimation.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality. As only one dose level (100 mg) was tested prior to termination of the study and multiple dose levels are required to investigate dose proportionality, hence dose proportionality could not be analyzed.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality. As only one dose level (100 mg) was tested prior to termination of the study and multiple dose levels are required to investigate dose proportionality, hence dose proportionality could not be analyzed.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality. As only one dose level (100 mg) was tested prior to termination of the study and multiple dose levels are required to investigate dose proportionality, hence dose proportionality could not be analyzed.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality. As only one dose level (100 mg) was tested prior to termination of the study and multiple dose levels are required to investigate dose proportionality, hence dose proportionality could not be analyzed.

PK Population: Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Accumulation ratio was calculated as AUC(0-tau) at Day 15 divided by AUC(0-tau) at Day 1 for GSK3145095.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Accumulation ratio was to be calculated as AUC(0-tau) at Day 15 divided by AUC(0-tau) at Day 1 for GSK3145095.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were collected at indicated time points for analysis of time invariance. Time invariance was calculated as AUC(0-tau) at Day 15 divided by AUC(0-infinity) at Day 1 for GSK3145095.

PK Population: Only those participants with data available at the specified data points were analyzed. Study was terminated in Part-1 during first escalation cohort "GSK3145095 50 mg BID", hence subsequent escalation cohorts were not initiated.

Blood samples were to be collected at indicated time points for analysis of time invariance. Time invariance were to be calculated as AUC(0-tau) at Day 15 divided by AUC(0-infinity) at Day 1 for GSK3145095.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were to be collected at indicated time points for the determination of plasma concentration of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were to be collected at indicated time points for the determination of Cmax of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were to be collected at indicated time points for the determination of AUC (0-tau) of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were to be collected at indicated time points for the determination of Cmin of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 2 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following single dose of GSK3145095 on Day 1.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following repeat dose of GSK3145095 on Day 15.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following single dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-tau) following single dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following single dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following single dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following single dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-t) following repeat dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of AUC (0-tau) following repeat dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of Cmax following repeat dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of tmax following repeat dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Blood samples were to be collected at the indicated time points for the determination of t1/2 following repeat dose of pembrolizumab.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.

Dose proportionality was to be evaluated for GSK3145095 using a fixed effects power model. Estimated slope was to be presented to express dose proportionality.

PK Population: Data were not collected for this endpoint as study was terminated during Part 1. Subsequent Part 3 was not initiated.